Psilocybin, LSD, MDMA, ketamine, DMT, and ibogaine have different pharmacology, duration, risk profiles, evidence bases, and legal pathways. Results from one substance should not be transferred to another.
Key facts
What the evidence supports
- 1“Psychedelic” is a broad category, not one mechanism.
- 2Clinical access for ketamine or research on MDMA does not legalize psilocybin.
- 3Duration and medical risks differ substantially by substance.
Evidence quality
What can and cannot be concluded
Definitions, pharmacology, and documented community practices
Some basic mechanisms and commonly described practices are documented. That does not establish a consumer treatment effect.
Clinical outcomes from repeated low doses
Controlled microdosing studies remain limited, with mixed or null findings and meaningful expectation effects.
Psilocybin, LSD, MDMA, ketamine, DMT, and ibogaine have different pharmacology, duration, risk profiles, evidence bases, and legal pathways. Results from one substance should not be transferred to another.
Common questions
Answered without a universal protocol
What is the main evidence limitation?+
Most reported benefits come from observational or self-reported data; controlled microdosing findings remain limited and mixed.
Does this page provide personal instructions?+
No. It explains evidence and terminology, not an individualized dose, schedule, or medical decision.
Where is the deeper research?+
Use the exact iMicrodosing.org companion linked near the top of the page for citations and fuller context.
Product-format context
Product descriptions, laboratory documentation, fulfillment policies, and client support remain on iMicrodosing.com. Deeper research remains on iMicrodosing.org.
Educational information only. Not medical advice. 21+ only.